The role of hypercoagulability in ischemic colitis

Scand J Gastroenterol. 2015 Jul;50(7):848-55. doi: 10.3109/00365521.2015.1010568. Epub 2015 Feb 5.

Abstract

Objective: The aim of this study is to evaluate the role of thrombophilia-hypercoagulability in ischemic colitis (IC).

Material and methods: Thrombophilia and fibrinogen were evaluated in 56 cases of IC and 44 controls with known predisposing factors but no evidence of IC. Thrombophilic factors tested were: protein C (PC), protein S, antithrombin (AT), resistance to activated protein C (APCR), lupus anticoagulant (LA), factor V G1691A mutation (FV Leiden), prothrombin G20210A mutation, methylenetetrahydrofolate reductase (MTHFR) gene C677T and A1298C mutations and plasminogen activator inhibitor-1 (PAI-1) gene 5G/4G and 4G/4G polymorphisms.

Results: In IC group were recorded: i) low levels of PC and AT (p = 0.064 and p = 0.022, respectively); ii) low levels of APCR (normal: >2, p = 0.008); iii) high levels of fibrinogen (p = 0.0005); iv) higher number of homozygotes for MTHFR A1298C and C677T mutations (p = 0.061 and p = 0.525 (Pearson chi-square), respectively); v) greater prevalence of 5G/4G and 4G/4G polymorphisms (p = 0.031 (Pearson chi-square)) and vi) higher incidence of LA-positive individuals (p = 0.037, Fischer's exact test). Multivariate analysis was performed to determine the effects of prothrombotic factors in IC. 5G/4G polymorphism of PAI-1 gene (odds ratio (OR) 12.29; 95% confidence interval (CI) 2.26-67.00), APCR (OR 0.089; 95% CI 0.011-0.699) and fibrinogen (OR 1.013; 95% CI 1.003-1.023) were determined as predictors of IC.

Conclusions: This study suggests that hypercoagulability, hereditary or acquired, plays an essential role in the manifestation of IC.

Keywords: activated protein C resistance; antithrombin III deficiency; fibrinogen; ischemic colitis; protein C deficiency; protein S deficiency; thrombophilia.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Colitis, Ischemic / drug therapy
  • Colitis, Ischemic / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Greece
  • Homozygote
  • Humans
  • Logistic Models
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Multivariate Analysis
  • Mutation
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic
  • Prospective Studies
  • Thrombophilia / genetics*

Substances

  • Plasminogen Activator Inhibitor 1
  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)

Supplementary concepts

  • Thrombophilia, hereditary